Cipla and Qilu Pharmaceutical Partner to Launch Keytruda Biosimilar in US
Cipla Ltd's subsidiary, Invagen Pharmaceuticals, has partnered with China's Qilu Pharmaceutical to license and supply QL2107, a biosimilar to the cancer drug Keytruda, in the US. Qilu will handle development, regulatory approval, and supply, while Cipla will manage US marketing. The collaboration aims to increase access to advanced cancer therapies and reduce treatment costs. Cipla focuses on oncology and complex generics, while Qilu has a broad biosimilar and innovative drug pipeline.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 44/100.
Outlets measured: english, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 3 Sept, 06:46 pm. Other outlets followed.
- 1